Analgesic drug use in patients with STEMI: Current perspectives and challenges

Huaigang Chen; Hong Wang; Bin Li; Lang Hong; Maobin Kuang; Liu Yang

doi:10.3389/fmed.2023.1148581

Analgesic drug use in patients with STEMI: Current perspectives and challenges

Front Med (Lausanne). 2023 Mar 22:10:1148581. doi: 10.3389/fmed.2023.1148581. eCollection 2023.

Authors

Huaigang Chen^{1

2}, Hong Wang², Bin Li², Lang Hong², Maobin Kuang^{1

2}, Liu Yang²

Affiliations

¹ Medical College of Nanchang University, Nanchang, Jiangxi Province, China.
² Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi Province, China.

Abstract

Therapy for patients with ST-elevation myocardial infarction (STEMI) has been a controversial topic since the introduction of thrombolytic agents in the 1980s. The use of morphine, fentanyl and lidocaine has increased substantially during this period. However, there is still limited evidence on their advantages and limitations. In this review, the clinical application, as well as future considerations of morphine, fentanyl and lidocaine in patients with ST segment elevation myocardial infarction were discussed.

Keywords: P2y12 receptor antagonists; STEMI; analgesic; lidocaine; morphine.

Publication types

Review